Shares of Alcon ALC were flat in after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share decreased 8.89% over the past year to $0.41, which were in line with the estimate of $0.41.
Revenue of $1,925,000,000 higher by 2.34% year over year, which beat the estimate of $1,890,000,000.
Guidance
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
Technicals
52-week high: $76.26
Company's 52-week low was at $39.37
Price action over last quarter: Up 10.91%
Company Profile
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun-off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with 41% of revenue in the U.S. market, and the firm has a strong presence in the European Union and Japan.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.